Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGG492 in MS-related spasticity
NCT01649050Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Mar 2018
01
Overview
A Phase 2 trial of selurampanel in Spasticity, sponsored by Novartis. Planned start Oct 2016; status: withdrawn.
02
Drugs
selurampanel
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT01649050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01649050.